Bio-Techne Cp (TECH) |
|
356.67 4.89 (1.39%)
|
01-21 01:07 |
|
Open: |
354.32 |
Pre. Close: |
351.78 |
|
High:
|
361.47 |
Low:
|
352.43 |
|
Volume:
|
196,416 |
Market Cap:
|
13,771M |
|
|
|
|
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates in two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers proteins and reagent solutions, including cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and T-Cell activation technologies. This segment also provides manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including Food and Drug Administration -regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for original equipment manufacturers and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays comprising the ExoDx Prostate test for prostate cancer diagnosis. This segment also manufactures and sells tissue-based in-situ hybridization assays for research and clinical use. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
361.506 - 362.765 |
362.765 - 363.917 |
|
Low:
|
348.8 - 350.424 |
350.424 - 351.912 |
|
Close:
|
354.102 - 356.36 |
356.36 - 358.428 |
|
Technical analysis |
as of: 2021-01-20 4:52:50 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 422.20  One year: 493.13 |
| Support: |
Support1: 324.52 Support2: 301.68 |
| Resistance: |
Resistance1: 361.47 Resistance2: 422.20 |
| Pivot: |
331.34 |
| Moving Average: |
MA(5): 344.79 MA(20): 328.50
MA(100): 284.85 MA(250): 253.75 |
| MACD: |
MACD(12,26): 11.05 Signal(9): 8.68 |
| Stochastic oscillator: |
%K(14,3): 93.41 %D(3): 87.53 |
| RSI: |
RSI(14): 76.10 |
| 52-week: |
High: 361.47 Low: 155.17 Change(%): 63.0 |
| Average Vol(K): |
3-Month: 16702 10-Days: 18241 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.TECH has closed below upper band by 1.5%. Bollinger Bands are 80.1% wider than normal. The large width of the bands suggest high volatility as compared to TECH's normal range. The bands have been in this wide range for 2 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Fri, 08 Jan 2021
Stocks That Hit 52-Week Highs On Friday - Benzinga
Thu, 07 Jan 2021
Stocks That Hit 52-Week Highs On Thursday - Benzinga
Mon, 28 Dec 2020
Stocks That Hit 52-Week Highs On Monday - Benzinga
Thu, 03 Dec 2020
The How and Why of Investing in Large-Cap Stocks - MarketBeat
Wed, 07 Oct 2020
FDA warns Battelle on reporting mask decontamination problems - Mass Device
Tue, 22 Sep 2020
12 surgical robotics companies you need to know | Page 7 - Medical Design & Outsourcing
|
Financial Analysis |
| Growth |
|
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
|
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Outperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
39 |
| Shares Float (M) |
38 |
|
% Held by Insiders
|
0.59 |
|
% Held by Institutions
|
95.81 |
|
Shares Short (K)
|
574 |
|
Shares Short P. Month (K)
|
508 |
Stock Financials |
|
EPS
|
6.260 |
|
EPS Est This Year
|
3.990 |
|
EPS Est Next Year
|
4.390 |
|
Book Value (p.s.)
|
37.290 |
|
Profit Margin
|
32.69 |
|
Operating Margin
|
21.81 |
|
Return on Assets (ttm)
|
5.2 |
|
Return on Equity (ttm)
|
19.0 |
|
Qtrly Rev. Growth
|
11.4 |
|
Gross Profit (p.s.)
|
12.515 |
|
Sales Per Share
|
19.675 |
|
EBITDA (p.s.)
|
5.566 |
|
Qtrly Earnings Growth
|
131.90 |
|
Operating Cash Flow (M)
|
231 |
|
Levered Free Cash Flow (M)
|
160 |
Stock Valuations |
|
PE Ratio
|
56.98 |
|
PEG Ratio
|
4.20 |
|
Price to Book value
|
9.56 |
|
Price to Sales
|
18.13 |
|
Price to Cash Flow
|
59.69 |
Stock Dividends |
|
Dividend
|
1.280 |
|
Forward Dividend
|
1.280 |
|
Dividend Yield
|
|
|
Dividend Pay Date
|
2020-11-26 |
|
Ex-Dividend Date
|
2020-11-12 |
|
7 Binary Options
|
|
Your Ad Here
|
|
